title: Measles virus.
abstract: Measles was an inevitable infection during the human development with substantial degree of morbidity and mortality. The severity of measles virus (MV) infection was largely contained by the development of a live attenuated vaccine that was introduced into the vaccination programs. However, all efforts to eradicate the disease failed and continued to annually result in significant deaths. The development of molecular biology techniques allowed the rescue of MV from cDNA that enabled important insights into a variety of aspects of the biology of the virus and its pathogenesis. Subsequently these technologies facilitated the development of novel vaccine candidates that induce immunity against measles and other pathogens. Based on the promising prospective, the use of MV as a recombinant vaccine and a therapeutic vector is addressed.
authors.affiliation: a Life Sciences and Vaccines Consultant; Bern, Switzerland.
authors.forename: Hussein Y
authors.initials: HY
authors.lastname: Naim
mesh_terms: D004337:Drug Carriers; D005822:Genetic Vectors; D006801:Humans; D008457:Measles / Q000453:epidemiology / Q000517:prevention & control; D008458:Measles Vaccine / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D008459:Measles virus / Q000235:genetics / Q000276:immunology* / Q000502:physiology*; D050130:Oncolytic Virotherapy / Q000379:methods; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
chemical_list: D004337:Drug Carriers; D008458:Measles Vaccine; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic
keywords: SSPE; live viral vaccine; measles; pathogenesis; recombinant vaccines; vaccine; viral vectors